Shui On Leung
Chief Executive Officer bij SINOMAB BIOSCIENCE LIMITED
Vermogen: 26 M $ op 31-03-2024
Profiel
Shui On Leung is the founder of Sinomab Bioscience Ltd., which was founded in 2001.
He holds the title of Chairman & Chief Executive Officer at Sinomab Bioscience Ltd.
from 2003 to the present.
Dr. Leung is currently the Director at Hong Kong Genome Institute.
In the past, he worked as the Associate Director-Molecular Biology Department at Immunomedics, Inc. from 1991 to 2000.
From 2000 to 2003, he served as the Managing Director at The Hong Kong Institute of Biotechnology Ltd.
Dr. Leung was also the Director at Novelmab Ltd.
from 2011 to 2018.
Dr. Leung obtained a doctorate degree from the University of Oxford in 1990.
He also holds undergraduate and graduate degrees from The Chinese University of Hong Kong, which were conferred in 1986.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SINOMAB BIOSCIENCE LTD.
11.88% | 31-01-2024 | 129 729 200 ( 11.88% ) | 26 M $ | 31-03-2024 |
Actieve functies van Shui On Leung
| Bedrijven | Functie | Begin |
|---|---|---|
| SINOMAB BIOSCIENCE LIMITED | Chief Executive Officer | 01-01-2003 |
| Hong Kong Genome Institute | Director/Board Member | - |
Eerdere bekende functies van Shui On Leung
| Bedrijven | Functie | Einde |
|---|---|---|
| Novelmab Ltd. | Director/Board Member | 01-07-2018 |
| The Hong Kong Institute of Biotechnology Ltd. | Chief Executive Officer | 01-08-2003 |
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 01-07-2000 |
Opleiding van Shui On Leung
| University of Oxford | Doctorate Degree |
| The Chinese University of Hong Kong | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SINOMAB BIOSCIENCE LIMITED | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
| The Hong Kong Institute of Biotechnology Ltd. | |
| Novelmab Ltd. | |
| Hong Kong Genome Institute |
